GlassScriptPhysician profile
Seth F Tatel
NPI 1144433467
$5,953.46
in general payments reported to CMS, 2019-2025
28 companies · $98.76 in 2025
The $98.76 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $718 · 2021: $1,689 · 2022: $1,135 · 2023: $919 · 2024: $132 · 2025: $98.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,149.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,416.99 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $657.06 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $450.60 | 2019-2023 | Entyvio |
| Boston Scientific Corporation | $372.69 | 2019-2025 | General - Biliary Devices, Watchman Flx |
| Celgene Corporation | $332.46 | 2022-2023 | Zeposia |
| Gilead Sciences, INC. | $332.29 | 2019-2023 | |
| Janssen Biotech, INC. | $195.17 | 2019-2022 | |
| Mauna Kea Technologies, INC. | $151.41 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $131.35 | 2020-2023 | Linzess |
| Echosens North America, INC. | $121.28 | 2019 | |
| Intercept Pharmaceuticals, INC. | $115.62 | 2019-2022 | |
| Pfizer INC. | $109.54 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $69.78 | 2021 | |
| Shionogi INC | $60.87 | 2019 | |
| Amgen INC. | $60.19 | 2021-2023 | Avsola, Amjevita |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $53.43 | 2019-2023 | Sutab |
| Daiichi Sankyo INC. | $52.32 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $51.13 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $46.86 | 2020-2022 | |
| Vivus LLC | $35.13 | 2019 | |
| Ardelyx, INC. | $25.70 | 2025 | Ibsrela |
| Redhill Biopharma INC. | $24.13 | 2020 | |
| Dova Pharmaceuticals | $19.84 | 2019 | |
| Ambu INC. | $17.42 | 2021 | |
| Genzyme Corporation | $14.36 | 2022 | |
| Amag Pharmaceuticals, INC. | $12.73 | 2021 | |
| Organon LLC | $11.98 | 2022 | |
| Allergan, INC. | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Tatel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.